Menu Search
Equities

Biontech SE

22UA:HAN

Biontech SE

Actions
  • Price (EUR)107.40
  • Today's Change-1.40 / -1.29%
  • Shares traded22.00
  • 1 Year change+17.63%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

  • Revenue in USD (TTM)3.17bn
  • Net income in USD-486.37m
  • Incorporated2019
  • Employees6.13k
  • Location
    Biontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
  • Phone+49 49 613190840
  • Fax+49 61 319084390
  • Websitehttps://www.biontech.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		22UA:GER since
announced		Transaction
value
Biotheus IncAnnounced13 Nov 202413 Nov 2024Announced6.59%800.00m
Data delayed at least 15 minutes, as of Nov 25 2024 11:53 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.